crohn’s disease
Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis
May 11, 2020Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis
The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …
Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease
February 18, 2020Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment …
Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease
February 17, 2020Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a …
Takeda’s subcutaneous formulation of Entyvio smashes primary endpoint in Crohn’s disease
July 23, 2019Manufacturing and Production, Research and Development Crohn’s disease, Entyvio, Takeda, crohn's disease, pharma
Takeda has unveiled new Phase 3 data for a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab), showing that the …
Takeda scores Japanese Entyvio approval in Crohn’s disease
May 22, 2019Research and Development, Sales and Marketing Crohn’s disease, Entyvio, Japan, crohn's disease, pharma
Takeda has announced that Japan’s drug regulator, the Ministry of Health, Labour and Welfare (MHLW), has approved Entyvio (vedolizumab) in …
Stem cells could ‘reset’ immune system in Crohn’s disease patients
August 8, 2018Research and Development Crohn’s disease, Stem cells, crohn's disease, trials
A clinical trial led by researchers at Queen Mary University, London is looking into ways in which patients with Crohn’s …
Takeda and TiGenix’s Alofisel becomes first donor-derived stem cell therapy approved in Europe
March 26, 2018Sales and Marketing Crohn’s disease, EU, Europe, European Commission, Takeda, TiGenix, crohn's disease, pharma
The European Commission has awarded approval to Takeda and TiGenix’s allogeneic expanded adipose-derived stem cell (eASC) therapy Alofisel (darvadstrocel) for …
Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal
October 30, 2017Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …
Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says
October 30, 2017Research and Development, Sales and Marketing Crohn’s disease, Pfizer, Remicade, crohn's disease, inflectra, pharma
Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …
NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara
May 3, 2017Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease
Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …
Celgene trial displays promising results for Crohn’s disease alternative treatment
October 17, 2016Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial
Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …
AstraZeneca agrees $250 million licensing agreement with Allergan
October 3, 2016Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease
Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …
Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials
May 26, 2016Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelara, crohn's disease, drug trial
Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials. The company said a significant …
J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease
March 18, 2016Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease
Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …
TiGenix says additional data for stem cell product affirms safety profile
March 9, 2016Research and Development Crohn’s disease, TiGenix, crohn's disease, drug trial
Belgian biotech firm TiGenix said the results of a 52-week follow-up study of its trial drug for a stem-cell condition …
